sintilimab: Clinical Trials

372 trials of sintilimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

149 unknown, 103 recruiting, 62 not yet recruiting, 31 completed. 372 Phase 2, 35 Phase 1, 16 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2372Unknown 149, Recruiting 103, Not yet recruiting 62, Completed 31, Active not recruiting 19, Terminated 4, Withdrawn 4
Phase 135Recruiting 12, Unknown 9, Not yet recruiting 8, Completed 3, Active not recruiting 2, Withdrawn 1
Phase 316Unknown 6, Not yet recruiting 5, Recruiting 3, Completed 2

Follow sintilimab: new trials by email Literature Review of sintilimab trials Research Report on sintilimab

Trials (filtered) newest first · largest first

All 372 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma
Sintilimab, Ipilimumab N01, Bevacizumab - Peritoneal Mesothelioma, First-line Therapy
Phase 2Not yet recruitingFudan University192026-10-302026-10-23
A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction Cancer
Ipilimumab N01, Sintilimab - Gastric / Gastroesophageal Junction Adenocarcinoma
Phase 2Not yet recruitingFudan University362026-10-202026-10-16
Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial
Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC)
Phase 2 / Phase 3Not yet recruitingYao Hongwei1202026-10-012026-10-19
Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial
Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC)
Phase 2 / Phase 3Not yet recruitingYao Hongwei1202026-10-012026-10-19
Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma
CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis
Phase 2Not yet recruitingSun Yat-sen University1382026-10-012026-09-17
A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer
Fruquintinib, Sintilimab, Irinotecan Hydrochloride Liposome Injection (II) - Stomach Neoplasms, Gastric Cancer
Phase 2Not yet recruitingCancer Hospital Chinese Academy of Medical Science, Shenzhen Center202026-10-012026-09-14
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
SYS6090 Injection + Bevacizumab Injection, SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection, Bevacizumab Injection + Sintilimab Injection - HCC - Hepatocellular Carcinoma
Phase 1 / Phase 2Not yet recruitingCSPC Megalith Biopharmaceutical Co.,Ltd.2882026-09-302026-08-12
Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer
Tafolecimab, Sintilimab - Colon Cancer, PCSK9 Inhibitor
Phase 2RecruitingDaping Hospital and the Research Institute of Surgery of the Third Military Medical University702026-09-202026-09-25
Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study
Sintilimab, ipilimumab, Radscopal Radiotherapy - Nasopharyngeal Carcinoma (NPC), Metastatic Nasopharyngeal Carcinoma
Phase 2Not yet recruitingSun Yat-sen University282026-09-012026-08-10
GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma
Gemcitabine (GEM), Etoposide Injection, Dexamethasone - Natural Killer/T-cell Lymphoma
Phase 2Not yet recruitingFudan University6202026-09-012026-08-17
Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Paclitaxel polymer micelles for injection and cisplatin combined with sintilimab - Esophageal Squamous Cell Carcinoma
Phase 2Not yet recruitingHebei Medical University Fourth Hospital322026-09-012026-09-02
SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer
SBRT + Ipilimumab N01 + Sintilimab + AG Chemotherapy - Pancreatic Cancer
Phase 2RecruitingShandong Cancer Hospital and Institute472026-08-052026-10-13
Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Trial
Ipilimumab Injection, Sintilimab injection, Lenvatinib - Renal Cell Carcinoma (Kidney Cancer), Immunotherapy
Phase 2Not yet recruitingWest China Hospital662026-08-012026-07-20
A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma
Sintilimab, disitamab vedotin - Sebaceous Gland Carcinoma
Phase 2Not yet recruitingWest China Hospital252026-08-012026-08-03
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 / Phase 3RecruitingInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.7202026-07-312026-08-14
Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial
Cetuximab, Irinotecan, Bevacizumab - Colorectal Neoplasms Malignant, Neoplasm, Metastatic
Phase 2RecruitingGuangdong Provincial People's Hospital1602026-07-232026-09-24
Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)
IBI310+ sintilimab + bevacizumab, IBI310+ sintilimab, sintilimab + bevacizumab - Resectable Hepatocellular Carcinoma
Phase 1 / Phase 2Not yet recruitingShanghai Zhongshan Hospital902026-07-202026-07-20
Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer
Sintilimab, Gossypol Acetate - Advanced Colorectal Cancer
Phase 2Not yet recruitingPeking University People's Hospital322026-07-152026-06-25
Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer
Multimodal Thermal Therapy (MTT) System, KRAS G12V mRNA Vaccine, Sintilimab - Pancreatic Ductal Adenocarcinoma, Liver Neoplasms
Phase 2Not yet recruitingRuijin Hospital202026-07-132026-08-04
Efficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer
Sintilimab + GC, SBRT 7Gy✖️5 QD - Biliary Tract Cancer (BTC)
Phase 2Not yet recruitingEastern Hepatobiliary Surgery Hospital1232026-06-152026-06-10

Showing 20 of 372. Sign in to see all of them.

Conditions studied

Carcinoma, Hepatocellular (44)  ·  Stomach Neoplasms (42)  ·  Carcinoma, Non-Small-Cell Lung (24)  ·  Colorectal Neoplasms (18)  ·  Esophageal Squamous Cell Carcinoma (13)  ·  Rectal Neoplasms (11)  ·  Lung Neoplasms (10)  ·  Nasopharyngeal Carcinoma (10)  ·  Pancreatic Neoplasms (8)  ·  Esophageal Neoplasms (7)  ·  Neoplasm Metastasis (7)  ·  Cholangiocarcinoma (6)  ·  Colonic Neoplasms (6)  ·  Neoplasms (6)  ·  Squamous Cell Carcinoma of Head and Neck (6)

Sponsors

Fudan University (41)  ·  Sun Yat-sen University (39)  ·  Tianjin Medical University Cancer Institute and Hospital (21)  ·  The First Affiliated Hospital with Nanjing Medical University (13)  ·  Zhejiang Cancer Hospital (13)  ·  West China Hospital (10)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (9)  ·  Innovent Biologics (Suzhou) Co. Ltd. (9)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (8)  ·  Ruijin Hospital (7)  ·  Peking Union Medical College Hospital (6)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (6)  ·  Henan Cancer Hospital (5)  ·  Sichuan University (5)  ·  Zhejiang University (5)

Countries

China (318)  ·  United States (4)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Peng Wang, MD (7)  ·  Hao Zeng, Doctor (2)  ·  Jing-wen Wang, M.D. (2)  ·  Kangshun Zhu, Dr. (2)  ·  Lin Wu (2)  ·  Mian Xi, MD (2)  ·  Yi-Long Wu (2)  ·  Yunpeng Liu, PhD (2)  ·  Zhen Zhang, M.D, PH.D (2)  ·  Aiping Zhou, M.D. (1)  ·  Baocai Xing, Doctor (1)  ·  Biyun Wang, Prof (1)

Results publications

PMID 34143971, PMID 34702811, PMID 15496622, PMID 18559976, PMID 19387333, PMID 20548096, PMID 20728210, PMID 21879261, PMID 22646630, PMID 24094768, PMID 24403232, PMID 25240821, PMID 25991832, PMID 26291008, PMID 26480849, PMID 26884585, PMID 27389519, PMID 28314688, PMID 28493288, PMID 28823862, PMID 29095678, PMID 29366520, PMID 29398921, PMID 29543938, PMID 29658856, PMID 29787422, PMID 29966520, PMID 29967015, PMID 30089078, PMID 30172698, PMID 30207593, PMID 30558224, PMID 30612710, PMID 30620669, PMID 30718072, PMID 30770362, PMID 30826965, PMID 30975638, PMID 31209394, PMID 31294749, PMID 31320661, PMID 31463890, PMID 32077550, PMID 32332722, PMID 32965635, PMID 33026938, PMID 33130217, PMID 33316218, PMID 33504550, PMID 33510460